EyeGene Inc. (KOSDAQ:185490)
South Korea · Delayed Price · Currency is KRW 1,450.00
-21.00 (-1.43%)
At close: Apr 2, 2026
EyeGene Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -15,706 | -12,128 | -21,106 | -25,953 | -34,569 |
Depreciation & Amortization | 2,077 | 2,343 | 2,137 | 1,291 | 1,070 |
Loss (Gain) From Sale of Assets | 846.61 | 543.46 | 27.65 | -1.81 | 4.18 |
Asset Writedown & Restructuring Costs | 2,099 | - | 82.57 | - | - |
Loss (Gain) From Sale of Investments | 6,324 | -12.05 | 1,539 | 776.79 | -432.18 |
Loss (Gain) on Equity Investments | 85.96 | -10.28 | 168.96 | 23.21 | - |
Stock-Based Compensation | 362.31 | -924.68 | 1,873 | 3,866 | 1,363 |
Provision & Write-off of Bad Debts | -2 | 16.06 | - | - | - |
Other Operating Activities | -1,940 | 695.89 | -4,594 | 3,170 | 1,564 |
Change in Accounts Receivable | 644.58 | -936.07 | 430.01 | -166.76 | 110.59 |
Change in Inventory | -165.73 | -529.78 | 442.8 | 276.39 | -69.91 |
Change in Accounts Payable | -378.11 | 1,209 | -393.15 | -1,030 | 364.01 |
Change in Other Net Operating Assets | -229.31 | -2,438 | -728.21 | -819.05 | 590.86 |
Operating Cash Flow | -5,981 | -12,171 | -20,120 | -18,568 | -30,004 |
Capital Expenditures | -102.69 | -1,514 | -1,385 | -767.86 | -2,378 |
Sale of Property, Plant & Equipment | 950 | - | 9 | 5.36 | - |
Cash Acquisitions | - | - | - | -800 | - |
Sale (Purchase) of Intangibles | -1,120 | -3,472 | -280.67 | -138.51 | -325.62 |
Investment in Securities | -3,673 | 13,933 | 7,329 | 18,950 | -54,498 |
Other Investing Activities | -1,410 | -1,608 | -0 | -0 | 524.7 |
Investing Cash Flow | -5,356 | 7,338 | 5,672 | 17,249 | -56,677 |
Long-Term Debt Repaid | -2,155 | -309.43 | -551.33 | -3,303 | -1,273 |
Net Debt Issued (Repaid) | -2,155 | -309.43 | -551.33 | -3,303 | -1,273 |
Issuance of Common Stock | 22,115 | - | 14,980 | - | 88,186 |
Other Financing Activities | 107.06 | 147.07 | 491.35 | 4,183 | -289.01 |
Financing Cash Flow | 20,068 | 646.52 | 17,909 | 879.97 | 86,624 |
Foreign Exchange Rate Adjustments | 38.23 | 116.1 | -10.2 | -164.41 | -16.96 |
Net Cash Flow | 8,769 | -4,071 | 3,450 | -603.17 | -74.02 |
Free Cash Flow | -6,084 | -13,685 | -21,506 | -19,336 | -32,382 |
Free Cash Flow Margin | -170.57% | -407.82% | -688.10% | -365.27% | -998.79% |
Free Cash Flow Per Share | -217.69 | -506.65 | -993.54 | -901.68 | -1709.67 |
Cash Interest Paid | 46.83 | 58.17 | 55.2 | - | 8.51 |
Cash Income Tax Paid | -95.17 | -79.84 | 106.81 | 147.41 | -13.65 |
Levered Free Cash Flow | -4,359 | -11,976 | -11,426 | -15,529 | -20,460 |
Unlevered Free Cash Flow | -3,966 | -11,539 | -11,136 | -15,282 | -19,364 |
Change in Working Capital | -128.58 | -2,695 | -248.55 | -1,740 | 995.55 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.